Vanda’s Second Quarter 2026: Fanapt Drives Growth Amid a Busy Pipeline Calendar

Q2 2026 snapshot: Fanapt remains the ballast

Vanda Pharmaceuticals Inc. (VNDA) reported results for the second quarter ended June 30, 2026. The company highlighted Fanapt net product sales of $36.0 million, up 23% year over year, with total prescriptions rising 31% in the quarter. The stock‑level takeaway here is the contribution from Fanapt to topline growth, even as the company tethers its narrative to a broader pipeline strategy.

Cash totaled $170.0 million as of June 30, 2026, and management said the liquidity is sufficient to fund operations through at least the end of 2027. On the revenue front, Vanda issued a full‑year 2026 revenue forecast (guidance) of $240 million to $290 million, signaling confidence in continued Fanapt performance and forthcoming pipeline catalysts.

Notably absent from the release is an EPS figure, so the analysis of earnings per share versus consensus remains outside the box for now. In investor terms, that means EPS consensus data and any potential earnings surprise will hinge on actual quarterly profitability as operating expenses evolve through the back half of 2026 and into 2027.

Pipeline and regulatory milestones: a calendar notched with PDUFAs and approvals

• BYSANTI (iloperidone) received FDA approval in Q1 2026; a commercial launch is anticipated in the second half of 2026, broadening the company’s mood-stabilizer and psychotropic portfolio.
• Quimilza (imsidolimab) — a BLA for generalized pustular psoriasis (GPP) is under FDA review; a PDUFA target action date is set for December 12, 2026, a milestone that could meaningfully alter the company’s dermatology and immunology exposure if approved.
• NEREUS™ (tradipitant) — became commercially available in Q2 2026, aimed at motion‑related vomiting; the company positions it as part of a motion‑related and GLP‑1 context line, with additional Phase III signals pending for the year-end results.
• HETLIOZ® (tasimelteon) is highlighted in relation to delayed sleep phase disorder, illustrating the ongoing diversification across sleep and circadian indications.
• Management notes that three Phase III trials are expected to read out by the end of 2026, underscoring the year’s critical cadence for de‑risking the pipeline and potentially expanding the revenue base beyond Fanapt.

Management perspective: scalability, costs, and the horizon

Mihael H. Polymeropoulos, M.D., Vanda’s President, CEO and Chairman, framed the quarter’s results within a broader optimization narrative: Fanapt’s ongoing growth supports the expected cadence of regulatory milestones and commercial launches. He emphasized that as Phase III programs advance and commercialization scale, operating expenses are anticipated to moderate later in 2026 and more markedly in 2027. In other words, the company is signaling a plan to convert pipeline activity into more sustainable operating leverage over time.

The lack of a disclosed EPS figure means the near‑term profitability trajectory remains a function of cost discipline and the timing of new product launches. Still, the tone suggests the company is balancing the cash burn that often accompanies a growing product portfolio with a deliberate pathway toward margin expansion as additional products reach scale.

Outlook for VNDA and peers: what to monitor

The 2026 revenue forecast provides a baseline for investor expectations, but the real hinge will be the pace at which BYSANTI and Quimilza reach commercial milestones, and whether NEREUS and other pipeline assets begin to contribute material revenue in 2027. If PDUFA action on Quimilza lands as anticipated in December 2026, the stock could see a narrative shift from a single‑product company to a multi‑product platform with a rising contribution from late‑stage assets.

From an industry lens, VNDA’s strategy mirrors a trend among mid‑cap biopharmas: push aggressive commercialization into the late 2020s while sequencing regulatory milestones that could unlock new revenue streams. The absence of EPS data makes this more of a top‑line story today, but the market will eventually pair revenue growth with earnings visibility as Phase III programs either confirm value or require repricing of risk in the stock’s multiple.

Investor takeaway: a cautious optimism with a calendar tether

VNDA’s report reinforces a stance where Fanapt remains the near-term driver, but the longer‑horizon thesis depends on a disciplined transition to multiple revenue streams from BYSANTI, Quimilza, and NEREUS. The company’s cash runway into 2027 supports a patient approach to these launches, while the PDUFA clock on late‑year regulatory activity introduces measurable catalysts that can tilt the risk–reward calculus for the stock and its sector peers.

For readers tracking EPS consensus and earnings surprises, this quarter’s document is a reminder that pipeline progress and regulatory milestones often matter more than a single quarter’s bottom line for biotech equities, especially when the company is investing aggressively to diversify its product slate.

Conclusion: a company vowing to diversify beyond a single product

As VNDA marches through 2026, investors are weighing the revenue forecast against the risk that several pipeline programs may not meet their anticipated timelines or success rates. The narrative is less about a dramatic earnings surprise and more about a staged transition—from Fanapt as a growth driver to a broader, multi‑product business with regulated milestones that could redefine the company’s earnings trajectory in 2027 and beyond.

Ticker: VNDA. Key terms to watch: EPS, EPS consensus, earnings surprise, revenue forecast, and the evolving revenue mix as BYSANTI, Quimilza, and NEREUS progress. If the calendar cooperates, the second half of 2026 could set the stage for a more balanced growth story—one that blends steady Fanapt momentum with the promise—and risks—of late‑stage launches and regulatory decisions.